Search PubMed⌕ Search

Biomedical subjects

E Schifferdecker

Publications and source records attributed to E Schifferdecker.

At least 19 recordsLinked to original sources
PubMed1992

HLA-DRB3 gene alleles in Caucasian patients with Graves' disease.

Graves' disease (GD) is a human leukocyte antigen (HLA) linked organ-specific autoimmune disease. In German GD patients the disease is associated with HLA specificities of the HLA-DRw52 family (HLA-DR3, -DR5, and DR6; HLA-DRB3 positive HLA haplotypes). Recently, a strong association with a HLA-DRB3 restriction fragment length polymorphism gene has been described. To study HLA-DRB3 alleles and their association with the disease, a large cohort of controls (n = 3724) and GD patients (n = 304) was analyzed. HLA-DR allelic combinations revealed an increase in HLA-DR3/DR5 heterozygous patients (relative risk 2.9; P < 0.001). HLA-DRB3 alleles, as defined by DNA typing in HLA-DR matched groups revealed a significant increase in DRB3*0101 homozygosity (relative risk 17.5; P < 0.001) in HLA-DR3 homozygous patients. In GD patients with ophthalmopathy (grade II or higher, according to Werner) DRB3*0101/*0202 heterozygosity revealed an increased relative risk of 5.5 (P < 0.001). Non-HLA-DR3 homozygous, DRB3*0101/*0202 heterozygous patients were at the highest risk for endocrine ophthalmopathy (relative risk 10; P < 0.001). Our data, based on DNA typing methods of HLA-D genes, provide evidence that the susceptibility is strongly associated with HLA-DRB3 genes.

Alleles↗
PubMed1991

Immunogenetic markers in patients with Graves' disease.

110 carefully characterized Caucasoid patients with Graves' disease were tested for HLA class I and class II antigens. Compared with Caucasian controls (n = 193), the frequencies of HLA B8, Cw7 and DR3 were significantly increased (pc less than 0.05). In the subgroups with and without exophthalmos, HLA A3 exhibited a negative but insignificant association with the eye involvement, while A19 and Cw2 showed positive, however even weaker correlations with eye disease. HLA DR5 was associated with relapsing thyrotoxicosis, whereas HLA DR7 and B12 were negatively correlated with relapse. These results confirm the positive correlation of HLA B8 and DR3 with Graves' disease and reveal a not yet observed association with Cw7. Reported correlations of antigen frequencies with eye disease and relapsing thyrotoxicosis could not be confirmed. Other previously unknown, however subtle differences in disease subgroups were observed.

Alleles↗
PubMed1991

HLA-DR3 and variations of the T cell receptor beta gene in Graves' disease.

The association of Graves' disease with two allelic forms of the T cell receptor beta-chain gene (Bgl II restriction fragments 9.2/10.0 kb) was analysed in Caucasians suffering from Graves' disease (N = 54), randomly selected controls (N = 68), and HLA-DR3 homozygous typing control subjects (N = 12). While gene frequencies did not vary in the latter two groups, a significant reduction of 9.2 kb homozygosity was observed in patients with Graves' disease (11 vs 32%, chi 2 = 7.68, p less than 0.01, RR = 0.26). The excess of the 9.2/10.0 kb heterozygosity in patients, which is restricted to the DR3-positive individuals, did not reach significance. The increase in heterozygosity of genomic T cell receptor beta-chain polymorphisms may be attributed to the role the beta-chain plays in autoantigen recognition in Graves' disease.

Bacterial Proteins↗
PubMed1990

[Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].

Twelve acromegalic patients were treated (mean +/- SD) 26 +/- 15 months with daily doses of 440 +/- 330 micrograms of the somatostatin analogue octreotide acetate (SMS 201-995, Sandostatin). The levels of somatomedin-C (Sm-C) decreased by 63% from 8.1 +/- 7.7 U/ml to 3.0 +/- 1.3 U/ml. Before starting therapy a long oral glucose tolerance test (oGTT) and a TRH test were performed both without and after s.c. injection of 100 micrograms octreotide. Under long-term treatment with octreotide four of twelve patients reached normal Sm-C-values. The GH levels of all of these patients were continuously suppressed to less than 2 ng/dl in an oGTT after a test dose of 100 micrograms octreotide s.c. till the end of the test (5 1/2 hours after octreotide injection). The other eight patients had a relief of acromegalic symptoms and five had a decrease of their Sm-C-levels, but none of them reached normal Sm-C-values. None of these patients had a continuous suppression of GH after a test dose of octreotide in an oGTT. Hyperprolactinemia (n = 4) was observed only in those patients with an insufficient response to octreotide. The GH-response to TRH showed neither without nor after injection of octreotide a correlation with the results of long-term treatment. Thus it is concluded that GH-suppression in a long oGTT after administration of a test dose of 100 micrograms octreotide acetate s.c. allows to identify those acromegalic patients who will benefit from long-term treatment with the somatostatin analogue octreotide acetate.

Acromegaly↗
PubMed1990

[Compliance problems in therapy with levothyroxine].

In order to evaluate problems with long-term levothyroxine therapy, the course of treatment in 185 patients of an endocrinological outpatient ward (88 with euthyroid goiter, 41 with overt or latent hypothyroidism, ten with Hashimoto's thyroiditis, 46 after resection of goiter) was analyzed retrospectively. Duration of therapy ranged from one to 28 years. Suppressive therapy of euthyroid goiter was stopped by the treating physician in eleven patients (11%), in five permanently. To the contrary, 30 patients (34%) stopped medication by themselves 31 times, 29 times, however, levothyroxine was restarted again. Observations in the group with latent hypothyroidism were similar. After operation levothyroxine therapy was stopped by the physician eight times, six times only for a limited time period. Eight patients (17%) decided to stop therapy without knowledge of the treating physician, but in all it was restarted later. The presented results show that the success of levothyroxine therapy of euthyroid goiter as well as of prophylaxis of goiter relapse after operation is threatened by dyscompliance of the patients. In goiter suppression therapy compliance is further challenged by a lack of consequence in therapy planning and guidance.

Adolescent↗
PubMed1990

[The course of diffuse hyperthyroidism in Basedow disease].

An investigation of a large group of patients with Graves' disease demonstrates that this autoimmune disorder of the thyroid is a chronic process with an often protracted course and therefore requires virtually life-long management. Drug therapy (with thionamides) is associated with a high rate of relapse of 60-70%-reliable criteria for the cessation of the autoimmune process are not available. Surgical therapy may also fail to provide lasting control of hyperthyroidism.

Adult↗
PubMed1990

Thyroid hormone binding inhibition in critically ill patients--who is the inhibitor?

In 31 severely ill patients of our intensive care unit an increased thyroid hormone binding inhibition detected by quantitative measurement of the effect of ether extracts of patients' sera on thyroxine tracer binding to TBG was found. As free fatty acids in serum were diminished in these patients, their postulated role as binding inhibitors in the "low T4 syndrome" of critically ill patients must be questioned. It cannot be excluded that THBI assays demonstrating this inhibition measure artefacts caused by heparine-induced in vitro lipolysis.

Acute Disease↗
PubMed1990

The HLA-DR4-associated DQw8 allele is confined to HLA-DR3/DR4 heterozygous type I (insulin-dependent) diabetics.

The HLA-DR4 specificity revealed a relative risk of 8.5 (chi 2 = 99.6; p less than 0.0001) when 193 type I diabetics were compared to 305 controls. Prevalence of the HLA-DR4-associated DQ types, i.e. DQw7 and DQw8, were determined, using a restriction fragment length polymorphism (RFLP) typing that combines the probe/enzyme combinations DQB/Taq I and DQB/Bam HI. The HLA-DQw8 specificity was confined to HLA-DR3/DR4 heterozygous patients when compared to controls (chi 2 = 4.9; p less than 0.025) or to all other DR4-heterozygous patients (chi 2 = 6.7; p less than 0.01). No association with HLA-DQw8 was seen in HLA-DR1/DR4 or HLA-DR"X"/DR4 (X not equal to 1,3,4) heterozygous patients. Due to the excess of HLA-DR3/DR4 patients the DQw8 allele is a risk factor in type I diabetics, but in HLA-DR1/DR4 and DRX/DR4 heterozygotes one might suggest that DQB1 and DRB combinations confer HLA-associated susceptibility.

Alleles↗
PubMed1989

[Injection aids for intermediate-term acting insulin. Experiences with the OptiPen].

Twenty diabetics conventionally treated with Depot H and/or Basal H Insulin Hoechst received the OptiPen as an injection aid for the corresponding U100 insulin preparations. Seventeen patients had such a positive opinion of the pen, that they wanted to continue using it. After 15.6 +/- 5.3 weeks of "pen therapy", the mean insulin dose remained unchanged. In the 14 patients who had been treated with insulin long before the change over to the pen, the mean HbA1 level showed no change (8.8 +/- 1.2% before versus 8.7 +/- 1.5% under pen therapy). The use of an injection aid--in this case the OptiPen--facilitates insulin therapy for the usually older diabetics treated with intermediate acting or mixed insulin, too. Technical problems over the long term were not encountered and the quality of metabolic control remained unchanged.

Adult↗
PubMed1989

Re-evaluation of eye muscle autoantibody determination in Graves' ophthalmopathy: failure to detect a specific antigen by use of enzyme-linked immunosorbent assay, indirect immunofluorescence, and immunoblotting techniques.

Sera from 41 patients with Graves' ophthalmopathy were investigated for presence of autoantibodies directed against eye muscle preparations using different methods: 1. ELISA with pork eye muscle membrane preparations; 2. Immunoblotting with glycoprotein preparations from human eye muscle; 3. Indirect immunofluorescence with human eye muscle sections. The ELISA was not suitable for detection of specific immunoglobulin binding with sera from patients suffering from endocrine ophthalmopathy. Immunoblotting exhibited only nonspecific binding to some muscle proteins; it could be prevented by pre-adsorption procedures and was not different from the pattern observed with skeletal muscle as antigen. The indirect immunofluorescence technique revealed no binding of Graves' sera to human muscle sections, whereas sera containing antibodies against skeletal muscle bound to eye muscle as well. Thus far, an antigenic structure of eye muscle specific for Graves' ophthalmopathy is not detectable with the methodology used here. The possibility that retroorbital connective tissue may be the main target of the autoimmune process must be considered.

Animals↗
PubMed1988

[Free fatty acids in the serum in critical diseases: do they play a role in the protein binding of thyroid hormones?].

As a contribution to the question if the elevated concentrations of free fatty acids in sera of critically ill patients described in literature play a role in the decrease of thyroid hormone levels in these patients, serum levels of the important free fatty acids were measured in 31 patients of our intensive care unit in the course of their disease using gas chromatography. After admission to the ward, only palmitoleic acid was significantly increased compared with 174 control persons, arachidonic acid was not different from the controls, palmitic, stearic, linoleic and linolenic acid were significantly decreased. In the course of the disease, no relevant changes were observed. The 21 patients not surviving their disease showed significantly lowered levels of palmitic, stearic and linoleic acid before death compared with the surviving patients at the end of the observation period. The hypothetical role of single free fatty acids as inhibitors of the binding of thyroid hormones to their transport proteins must be questioned because of the results.

Adolescent↗
PubMed1988

Linkage of HLA-DR beta specific restriction fragment length polymorphisms with Graves' disease.

HLA-DR3 positive patients with Graves' disease (6 homozygotes, 7 heterozygotes, i.e. yielding 19 haplotypes) were studied by restriction fragment length polymorphism analysis using TaqI as restriction enzyme in order to look for polymorphisms in the HLA-DR3 allele of the human major histocompatibility complex. Polymorphic TaqI fragments of 11.6, 9.8 and 5.8 kb, each corresponding to HLA-DR beta sequences, were shown to differ in their prevalence in patients with Graves' disease and controls. The prevalence of DR3 polymorphisms in a total of 35 HLA-DR3-containing haplotypes was markedly different within patients with Graves' disease and Caucasian controls. Whereas a 11.6 kb fragment was rare in Graves' disease (2/19 haplotypes vs 8/16 in controls), the inverse ratio was found for a 9.8 kb fragment, with a prevalence of 17/19 and 8/16 haplotypes, respectively. A polymorphic fragment of 5.8 kb was exclusively seen in two DR3-containing haplotypes of patients with Graves' disease. Our data provide evidence that a DNA polymorphism of the HLA-DR beta genes, which is also reflected at the product level, is linked to Graves' disease.

Cell Line↗
PubMed1987

[Plasma renin activity and aldosterone behavior in critically ill patients].

To investigate the influence of critical illness on plasma renin activity and aldosterone levels and to examine potential inhibitory effects of dopamine therapy on aldosterone responsiveness, we measured plasma renin activity, and potassium and creatinine in serum, as well as the responses of aldosterone, cortisol and prolactin levels to TRH 200 micrograms i.v. + Synacthen 0.25 mg i.v. in 63 unselected, critically ill patients (32 females, 31 males, aged 18-84 years). Of the patients 19 received dopamine treatment (3-13 micrograms/kg/min i.v.); 21 of the patients died in the further course of their disease. Plasma renin activity was increased in 66.7% of the patients and aldosterone levels were elevated in 90.5% of the patients. There were correlations (P less than 0.05) of lethality with plasma renin activity and cortisol levels and correlations (P less than 0.01) of aldosterone concentrations with plasma renin activity and cortisol levels. Whereas dopamine treatment had no inhibitory effect on aldosterone levels before and after stimulation, prolactin stimulation was decreased in dopamine-treated patients. Thus, dopamine does not generally lose its potency of hormone inhibition in critically ill patients, but has no influence on the secondary aldosteronism developing regularly in the early phase of critical illness, which is apparently mainly due to the stimulatory effect of ACTH (or ACTH-related pituitary peptides) and is considered an epiphenomen of the stress mechanisms acting upon the patients in this condition.

Aldosterone↗